Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 3, 2001, Pages 232-236

  Recchia, F ^a,b,e   Sica, G ^c   De Filippis, S ^a   Rosselli, M ^b   Pompili, P L ^b   Rea, S ^b,d  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Ferri CROFI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Oncologia Chirurgica Università degli Studi de L'Aquila   (Italy)

^e NONE   (Italy)

Author keywords

Chemotherapy; Hormone refractory status; Prostate specific antigen; Prostatic carcinoma

Indexed keywords

EPIRUBICIN; FLUOROURACIL; MITOMYCIN C; PROSTATE SPECIFIC ANTIGEN;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PROSTATE CARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; EPIRUBICIN; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0034987706     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200106000-00004     Document Type: Article

References (17)

1. Prostatic carcinoma
2. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
3. The chemotherapy of prostatic adenocarcinoma
4. Doxorubicin, mitomycin-C, and 5-fluorouracil in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on staging of metastatic prostate cancer
5. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormonal refractory adenocarcinoma of the prostate: A Southwest Oncology Group study
6. Chemotherapy of hormonally refractory advanced prostatic adenocarcinoma. A comparison of combined versus sequential treatment with mitomycin-c, doxorubicin, and 5-fluorouracil
7. Weekly chemotherapy in advanced prostatic cancer
8. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
9. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations
10. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
11. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostatic cancer
12. Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors
13. Nonparametric estimation from incomplete observations
14. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
15. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
16. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer. A case report and review of the literature
17. Altered tumor (Tu) marker expression after chemo-immunotherapy. Preliminary report